Diana Bilton is Honorary Clinical Senior Lecturer and Director of the Adult Cystic Fibrosis Service at Royal Brompton Hospital.
Diana trained in Manchester graduating in 1984.After completing general training she became a UK Cystic Fibrosis Trust research fellow with Professor Kevin Webb examining the influence of antioxidant status on pulmonary and pancreatic disease . This early research inspired Diana's career long interest in evaluating new diagnostic and therapeutic approaches to the continued vicious cycle of infection and inflammation in Cystic Fibrosis and Non CF Bronchiectasis.
Diana has been global chief investigator on trials of new therapies for Cystic Fibrosis and nonCF Bronchiectasis. Recent studies have included randomised trials of Inhaled Dry Powder Mannitol as well as investigation of novel inhaled antibiotic preparations.
Diana is joint PI with Dr Jane Davies of the European CF Society Clinical Trials Network site at Royal Brompton .
et al., 2017, Ethnicity impacts the cystic fibrosis diagnosis: A note of caution., J Cyst Fibros
et al., 2017, Longitudinal assessment of sputum microbiome by sequencing of the 16S rRNA gene in non-cystic fibrosis bronchiectasis patients, Plos One, Vol:12, ISSN:1932-6203
et al., 2017, Phase I Studies of Acebilustat: Biomarker Response and Safety in Patients with Cystic Fibrosis, Cts-clinical and Translational Science, Vol:10, ISSN:1752-8054, Pages:28-34
et al., 2017, Pseudomonas aeruginosa adaptation and diversification in the non-cystic fibrosis bronchiectasis lung, European Respiratory Journal, Vol:49, ISSN:0903-1936
et al., 2017, A treatment evaluator tool to monitor the real-world effectiveness of inhaled aztreonam lysine in cystic fibrosis., J Cyst Fibros